Oxford Biodynamics Share Discussion Threads

[wooster4] 18/1/2024 10:01

they're talking about prostate cancer on bbc 5 live at the moment - mentioned about how bad the current psa tests are.

[hatfullofsky] 18/1/2024 09:31

More pain today I fear.

This the problem statement :

Cash resources as predicted in the budget are very sensitive to changes in the assumptions related to these uncertainties: this was noted in two alternative scenarios considered by the Directors: a "possible" scenario that reflects significantly reduced test volumes compared to the budget and a "downside" scenario with still lower test volumes and no new pharma projects assumed. Without any remedial action to reduce costs or delay expenditure, in these scenarios the Group and Company would need to obtain additional funds during the second quarter of 2024 in order to continue as a going concern.

[waldron] 18/1/2024 08:59

London S.E. 08:39:22 18/01/2024 GMT



24.82 GBX -5.64%

[hatfullofsky] 18/1/2024 08:34

I agree, partner up on the PSE and get royalties and a cash injection

[thehitman1] 18/1/2024 08:19

Did say pump and dump

[jambam] 18/1/2024 08:01

Partnership deal on the csrds

[waldron] 17/1/2024 22:34

Conclusion and focus for 2024

At the start of the financial year, our primary focus was expected to be on growing orders of EpiSwitch CiRT. The OBD team achieved this objective, in addition to meeting the extra challenge of expediting the development and launch of EpiSwitch PSE. I am pleased that we set ourselves this stretch goal - as well as the obvious promising commercial prospects for the Group, there are clear benefits for patients and their families to having PSE launched and available as soon as possible.

We remain committed to working with commercial and other partners to provide unique and critical insight with our 3D genomics technology. At the same time, we see the unpredictable pace at which such projects are often agreed as validation of OBD's determination to develop our own products, directly building the market for 3D genomics ourselves.

Looking forward to 2024, my team and I will be focused on four main areas:

-- Following the initial introduction of EpiSwitch PSE into the market last year, with the leadership of Dr Arrivo, we aim to drive significant awareness and adoption by targeting large organization accounts and partnering to generate nationwide access and distribution of the test. This will involve extensive business development and sales and marketing activity, within our available resources. We will also bring PSE online in our UK clinical laboratory by the end of March 2024.

-- We will continue to drive adoption and increase orders of EpiSwitch CiRT. Dr Mathis's approach will allow us to capitalize on the foundation of the 750 tests used to date. We will focus our efforts by identifying insights from the data such as usage niches, algorithm alignment and key accounts. Distilling the HEOR story and petitioning for adoption into NCCN Guidelines and compendia will put the test in the hands of a greater number of oncologists, not just the early adopters. We expect this will also help us to enter into further direct agreements with insurers and healthcare delivery networks (IDNs, GPOs and hospitals).

-- We will continue the recently initiated confidential discussions with third parties regarding our two most advanced pipeline assets, EpiSwitch NST for colorectal/bowel cancer and EpiSwitch SCB for canine cancer and will assess and explore opportunities for monetizing these and other programs from our extensive portfolio of deployable 3D genomic tests.

-- Finally, we will continue to work on internal and grant- and award-funded research and development and on projects for commercial partners.

We are already accelerating on all of these fronts and look forward to reporting back to shareholders later in the year.

Dr Jon Burrows

Chief Executive Officer

Oxford BioDynamics Plc

[dudishes] 17/1/2024 18:48

Got that wrong, 29 and will hold.

I think most have faith?

[jambam] 17/1/2024 18:03

Cash until Q2.good mention on vox today. Ignore the noise today.

[secretsqu] 17/1/2024 17:46

There's a lot of feedback over on LSE.

[hatfullofsky] 17/1/2024 17:31

rar100 - sounds good to me, see you

[rar100] 17/1/2024 16:27

Big Pharma taking over monetizing on tests and leaving OBD to do science only is very obviously the best scenario as these results show all too clearly.
Good at science, clueless at business. No idea how to treat shareholders as their rns's show.

I won't bother to look at this crowd until there's news of a takeover in some form.

[hatfullofsky] 17/1/2024 16:09

Any feedback from the webinar ?

[hatfullofsky] 17/1/2024 16:08

https://news.sky.com/story/the-king-will-attend-hospital-for-prostate-treatment-palace-says-13049569May keep the light shining on Prostate detection

[jambam] 17/1/2024 13:56

Could be some interesting news in webinar at 3. Good luck

[saint in exile] 17/1/2024 12:27

Sold before news as I suspected this would happen.Buying them back now as the bigger picture is yet to come

[hatfullofsky] 17/1/2024 08:55

Wouldn't it be nice if the simply published there test performed metrics, quarterly

[givmesunshine] 17/1/2024 08:29

Agree Hat - very disappointed, I hoped that were holding back the CIRT test numbers for a nice big update, but looks like the strategy is not planning out as yet

[babbler] 17/1/2024 08:29

And what did you expect. It was pre all recent news. That's behind and now monetisation coming in. Now's the time to be buying on dips imo. But who knows... Long term looks great short term pain for recent buyers above today's price.

[hatfullofsky] 17/1/2024 08:06

-- Total PSE orders to date of 144, total CiRT orders to date of 770

[hatfullofsky] 17/1/2024 08:04

Not a great read, especially in this market.

CiRT slowed in summer (as we predicted)
Good take up of PSE
10.2m Op loss
8.3m cash outflow / 700k per month
£5.3m cash at 30/09/23
Cash runway for 7 months to 30/04/23 (without any additional cash inflow)